RA Capital Management’s AN2 Therapeutics ANTX Stock Holding History

RA Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,999,997	Closed	-$2.14M	–	90
2024 Q3	$2.14M	Sell	1,999,997 -3,551,298	-64%	-$6.16M	0.02%	79
2024 Q2	$11.9M	Hold	5,551,295	–	–	0.16%	61
2024 Q1	$18M	Hold	5,551,295	–	–	0.23%	65
2023 Q4	$114M	Hold	5,551,295	–	–	1.78%	14
2023 Q3	$89.3M	Buy	5,551,295 +1,777,778	+47%	+$20.1M	1.76%	16
2023 Q2	$32.1M	Hold	3,773,517	–	–	0.61%	40
2023 Q1	$37.2M	Hold	3,773,517	–	–	0.84%	36
2022 Q4	$36M	Hold	3,773,517	–	–	0.73%	37
2022 Q3	$65.6M	Buy	3,773,517 +25,128	+0.7%	+$293K	1.4%	23
2022 Q2	$29.1M	Buy	3,748,389 +81,726	+2%	+$1.08M	0.77%	37
2022 Q1	$55.3M	Buy	+3,666,663	New	+$55.6M	1.21%	24

Other funds holding ANTX

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

RA Capital Management's ANTX Position: Q4 2024 in Review

RA Capital Management sold out of AN2 Therapeutics (ANTX) in Q4 2024, closing a stake of 1,999,997 shares — an estimated $2.14M sold.

RA Capital Management first reported a position in ANTX in Q1 2022 and held it in 11 quarters. The position peaked at $114M in Q4 2023. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2024.

RA Capital Management reported no remaining AN2 Therapeutics position as of Q4 2024 after selling out during the quarter.
RA Capital Management sold 1,999,997 AN2 Therapeutics shares in Q4 2024, an estimated $2.14M.
RA Capital Management first reported a position in AN2 Therapeutics in Q1 2022 and held it in 11 quarters.
RA Capital Management's AN2 Therapeutics position peaked at $114M in Q4 2023.
37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2024.

Based on RA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.